Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

GTX Inc (GTXI) Com Stk USD0.001

Sell:$0.88 Buy:$1.08 Change: $0.01 (0.96%)
NASDAQ:1.08%
Market closed |  Prices as at close on 21 May 2019 | Switch to live prices |
Sell:$0.88
Buy:$1.08
Change: $0.01 (0.96%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 21 May 2019 | Switch to live prices |
Sell:$0.88
Buy:$1.08
Change: $0.01 (0.96%)
Market closed |  Prices as at close on 21 May 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Contact details

Address:
17 W Pontotoc Ave Ste 100
MEMPHIS
38103-3826
United States
Telephone:
+1 (901) 5239700
Website:
www.gtxinc.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GTXI
ISIN:
US40052B2079
Market cap:
$25.01 million
Shares in issue:
24.05 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Robert Wills
    Executive Chairman of the Board
  • Marc Hanover
    Chief Executive Officer, Director
  • Jason Shackelford
    Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer
  • Henry Doggrell
    Vice President, Chief Legal Officer, Secretary
  • Diane Young
    Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.